RECRUITING

NVG-291 in Spinal Cord Injury Subjects

Description

A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects

Conditions

Spinal Cord InjuriesChronic Spinal Cord InjurySubacute Spinal Cord Injury
Talk to us

Related Conditions:

Spinal Cord InjuriesChronic Spinal Cord InjurySubacute Spinal Cord Injury

Study Overview

On this page

Study Details

Study overview

A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects

A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects (CONNECT)

NVG-291 in Spinal Cord Injury Subjects

Condition
Spinal Cord Injuries
Intervention / Treatment

-

Contacts and Locations

Chicago

Shirley Ryan AbilityLab, Chicago, Illinois, United States, 60611

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. For Chronic cohort 1: Less than or equal to Level 14.
  • 2. For Subacute cohort 2: Less than or equal to Level 10.
  • 1. In two specific target muscle groups (Cohort 1)
  • 2. In one specific target muscle group (Cohort 2)
  • 1. History of a cardiac pacemaker or pacemaker wires, OR
  • 2. Ferromagnetic metallic particles in the body, OR
  • 3. Baclofen pump, OR
  • 4. Vascular clips in the head, OR
  • 5. Prosthetic heart valves, OR
  • 6. Severe claustrophobia impeding ability to participate in an imaging study.

Ages Eligible for Study

18 Years to 75 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

NervGen Pharma,

Daniel Mikol, M.D. Ph.D., STUDY_DIRECTOR, NervGen Pharma

Study Record Dates

2026-04